Cspc Pharmaceutgr Adr4 Stock Net Asset
| CVGU Stock | EUR 2.26 0.04 1.74% |
CSPC PHARMACEUTGR ADR4 fundamentals help investors to digest information that contributes to CSPC PHARMACEUTGR's financial success or failures. It also enables traders to predict the movement of CSPC Stock. The fundamental analysis module provides a way to measure CSPC PHARMACEUTGR's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CSPC PHARMACEUTGR stock.
CSPC |
CSPC PHARMACEUTGR ADR4 Company Net Asset Analysis
CSPC PHARMACEUTGR's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, CSPC PHARMACEUTGR ADR4 has a Net Asset of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—General (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
CSPC Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CSPC PHARMACEUTGR's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CSPC PHARMACEUTGR could also be used in its relative valuation, which is a method of valuing CSPC PHARMACEUTGR by comparing valuation metrics of similar companies.CSPC PHARMACEUTGR is currently under evaluation in net asset category among its peers.
CSPC Fundamentals
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.22 % | |||
| Shares Outstanding | 2.98 B | |||
| Price To Earning | 18.49 X | |||
| Revenue | 30.72 B | |||
| Gross Profit | 21.14 B | |||
| EBITDA | 7.56 B | |||
| Net Income | 5.47 B | |||
| Cash And Equivalents | 9.28 B | |||
| Cash Per Share | 3.10 X | |||
| Total Debt | 316.71 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 9.41 X | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 24.75 K | |||
| Beta | 0.75 | |||
| Market Capitalization | 12.8 B | |||
| Z Score | 24.0 | |||
| Annual Yield | 0.03 % | |||
| Last Dividend Paid | 0.24 |
About CSPC PHARMACEUTGR Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CSPC PHARMACEUTGR ADR4's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CSPC PHARMACEUTGR using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CSPC PHARMACEUTGR ADR4 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CSPC Stock
CSPC PHARMACEUTGR financial ratios help investors to determine whether CSPC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CSPC with respect to the benefits of owning CSPC PHARMACEUTGR security.